stocktrademan
6 years ago
GHDX buy 69.34
bull flag
earnings winner
an easy trade on any chart is to just look for the 20 above the 50 and then wait for the price to touch the averages for a bull flag and a measured move...the trade is on as long as the 20 is above the 50...why 20 and 50 because they are near fibonacci numbers 21 and 55.
fibonacci sequence:
0, 1, 1, 2, 3, 5, 8, 13, 21, 34, 55, 89, 144, 233, 377, 610, 987, 1597, 2584, ...
https://www.google.com/search?&q=fibonacci+sequence
This can work with other fibonacci numbers for the moving averages also just pick one, skip one, then use the next for the averages on the chart.
https://www.genomichealth.com/
normal chart
log chart
TheFinalCD
11 years ago
Genomic Health Announces Presentation of New Oncotype DX® Studies Underscoring Unique Value of the Test in Early-Stage Breas...
Print
Alert
Genomic Health, Inc. (MM) (NASDAQ:GHDX)
Intraday Stock Chart
Today : Saturday 14 December 2013
Click Here for more Genomic Health, Inc. (MM) Charts.
REDWOOD CITY, Calif., Dec. 14, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from three studies of its Oncotype DX® breast cancer test presented at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), reinforcing the unmatched value of the test to patients and physicians worldwide. Oncotype DX remains the only genomic test to predict chemotherapy benefit, delivering clinically important and practice-changing information not provided by any other test.
(Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO)
"Ten years ago, the first validation study of the Oncotype DX assay was presented at SABCS, ushering in a new era of personalized breast cancer treatment," said Steven Shak, M.D., executive vice president of research and development, Genomic Health. "Over the last decade, in partnership with many collaborators, we have demonstrated that the rigorous validation of genomic information can transform cancer treatment. Moving forward we will continue to apply our world-class science to lead the translation of massive amounts of genomic data into practice-changing results for treatment planning from screening and surveillance, through diagnosis, treatment selection and monitoring."
Fourth Head-to-Head Comparison Study to Show Oncotype DX Results Are Different from Tests Limited to Prognosis
A study examining three commercially available genomic tests evaluated if the information they provide is equivalent. Specifically, results revealed a more than 44 percent discordance with other assays studied when compared to Oncotype DX, highlighting the potential to misclassify and mistreat patients if other assays are used to make a decision regarding chemotherapy treatment. Oncotype DX is the only test included in treatment guidelines for both prognosis and the prediction of chemotherapy benefit and widely reimbursed by public and private payors for treatment decision making.
"As a clinical investigator and medical oncologist with a practice dedicated to breast cancer, I practice evidence-based medicine and therefore utilize genomic testing to gain an understanding of the breast tumor's individual biology to help guide critical treatment decisions," said Lori J. Goldstein, M.D., Fox Chase Cancer Center, Philadelphia, PA. "If the question is whether or not to use chemotherapy, the answer is clear. To date, Oncotype DX is the only test that has been appropriately studied and validated to answer the specific question of which ER positive breast cancer patients need chemotherapy in addition to standard-of-care hormonal therapy."
Researchers conducting an analysis of 135 patient samples using Oncotype DX and a 70-gene prognostic test demonstrated that 33 percent of high-risk patients by the 70-gene assay were classified as low risk by the Oncotype DX Recurrence Score, indicating that these patients would likely receive no benefit from chemotherapy. Further, five percent of the 70-gene assay low-risk patients were classified as high risk by the Oncotype DX test, indicating that they would likely have a significant, potentially life-saving benefit from chemotherapy.
"Previous studies have demonstrated similar results and suggested that this high level of discordance is related, in part, to the fact that the 70-gene assay was developed in untreated patient populations without consideration of estrogen receptor status or the impact of hormonal treatment which is today's standard of care," said Phil Febbo, M.D., chief medical officer, Genomic Health and former professor of medicine at the University of California, San Francisco.
These findings are consistent with previously reported results at the 2013 ASCO annual meeting (Schneider et al), 2012 San Antonio Breast Cancer Symposium (Poulet et al), 13th St. Gallen International Breast Cancer Conference (Poulet et al) and 2011 ASCO Breast Symposium (Dendaluri et al).
Two additional studies were presented:
•"Discordance in hormone receptor (HR) assessment by IHC and RT-PCR in an estrogen receptor (ER) low-positive group (1-10% positive cells): Does accurate assessment of HR status require dual testing?" (Abstract: P3-05-08, Singh B) The results of this study demonstrate the importance of accurate assessment of ER status to ensure appropriate hormonal treatment, and the results highlight the value of the Oncotype DX single gene analysis of ER and PR in providing additional information regarding breast cancer molecular subtyping.
•"Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by Recurrence Score and conventional parameters in clinical routine" (Abstract: P6-05-11, Harbeck N) The run-in phase of the ADAPT HR+/HER2- trial has demonstrated the feasibility of the ADAPT trial design. The main phase of the ADAPT HR+/HER2- trial will evaluate whether adding testing of tumor tissue following short-term hormonal neoadjuvant treatment adds to the treatment planning value already provided by standard Oncotype DX testing of the primary tumor prior to treatment.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from screening and surveillance, through diagnosis, treatment selection and monitoring. Genomic Health's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease, and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of September 30, 2013, more than 19,000 physicians in over 70 countries had ordered nearly 400,000 Oncotype DX tests. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth. To learn more about OncotypeDX tests, visit: www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.
bpvitale
14 years ago
NGNM – worth a look...
I hope GHDX shareholders are feeling pretty good about GE's announcement last week to purhcase CLRT for over 5x sales, I know I am. Another small cancer diagnostics company worth taking a hard look at is NGNM.
The company just reported solid third quarter results, with revenue growth of 19% YoY and volume growth of 29% YoY. I think management did a great job on the conference call and seem to be making all of the right moves. With much of the heavy lifting now behind the company, business should begin to improve each quarter going forward, and probably one of the reasons why management was comfortable enough to provide 2011 estimates. NGNM now expects 2011 revenues to be in the range of $41-45 million, which would imply a 25-30% increase in sales next year.
Clearly, the business has bottomed and the business model has reached critical mass.
At 5x 2011 sales of $41 million, NGNM would fetch between $4-5 per share from a strategic buyer.
So at $1.10, the stock appears to be way undervalued and a great opportunity for any small-cap investor, and I still believe NGNM is going to be a big winner, even more than ever, after listening to the third quarter conference call.
surf1944
16 years ago
Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress
Tuesday August 5, 4:02 pm ET
- Product Revenue Increased 81 Percent; Tests Delivered Grew 69 Percent Year over Year -
- Net Loss Continued to Narrow -
- Company Updates 2008 Guidance -
- Conference Call Today at 4:30 p.m. ET -
REDWOOD CITY, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX - News) today reported financial results and business progress for the quarter ended June 30, 2008.
Total revenue increased to $27.8 million in the second quarter of 2008 compared to $14.7 million in the second quarter of 2007. Product revenue from the Oncotype DX® breast cancer assay was $26.3 million in the second quarter of 2008, an increase of 81 percent compared to $14.6 million in the second quarter of 2007, the result of continued growth in adoption and reimbursement. Contract revenue was $1.5 million in the second quarter of 2008, compared to $135,000 in the second quarter of 2007, reflecting continued collaboration with pharmaceutical partners to explore the development of tests for predicting benefit from certain targeted therapies.
"We believe the increasing impact of personalized medicine and our investment in Oncotype DX are reflected not only in our strong revenue and growth in tests delivered, but also in the narrowing of our net loss in the second quarter," said Randy Scott, Ph.D., chairman and chief executive officer of Genomic Health. "While we work to further reduce our net loss, we will continue to invest in our product pipeline and expand our commercial efforts outside of the United States, which we expect to be important components of future growth."
Additional Second Quarter 2008 Financial Results
During the second quarter of 2008, approximately 51 percent of product revenue was recorded on an accrual basis and recognized at the time the test results were delivered, reflecting established payment patterns from payors with coverage policies in place.
Cost of product revenue was $6.9 million in the second quarter of 2008, compared to $4.2 million for the second quarter of 2007. Research and development expenses for the second quarter of 2008 were $7.3 million, compared to $5.2 million for the same period in 2007. Selling and marketing and general and administrative expenses for the second quarter of 2008 were $18.1 million, compared to $12.9 million for the same period in 2007. Included in second quarter 2008 operating expenses was $2.3 million of stock-based compensation expense, compared to $1.5 million in the same period in 2007.
Net loss was $4.1 million in the second quarter of 2008, compared to $7.2 million in the second quarter of 2007. Basic and diluted net loss per share was $0.15 in the second quarter of 2008, compared to a net loss per share of $0.28 in the second quarter of 2007.
Financial Results for Six Months Ended June 30, 2008
Total revenue for the six months ended June 30, 2008 was $51.2 million, compared to $28.8 million for the first six months of 2007. Product revenue for the six months ended June 30, 2008 was $49.7 million, compared to $27.7 million for the first six months of 2007. Contract revenue constituted the balance of revenue for the first six months of 2008 and 2007.
Cost of product revenue for the six months ended June 30, 2008 was $12.7 million, compared to $8.0 million for the comparable period in 2007. Research and development expenses for the first six months of 2008 were $13.7 million, compared to $10.4 million in the first six months of 2007. Selling and marketing and general and administrative expenses for the first six months of 2008 were $36.3 million, compared to $25.2 million in the first six months of 2007. The increase in expenses includes stock-based compensation expense of $4.5 million in the first six months of 2008 compared to $2.8 million for the same period in 2007.
Net loss for the six months ended June 30, 2008 was $10.7 million, compared to $14.0 million for the first six months of 2007. Basic and diluted net loss per share was $0.38 for the six months ended June 30, 2008, compared to a net loss per share of $0.55 for the first six months of 2007.
Cash and Cash Equivalents
Cash and cash equivalents and investments at June 30, 2008 were $60.6 million compared to $65.4 million at March 31, 2008 and $68.4 million at December 31, 2007.
Updated 2008 Outlook and Financial Guidance
The company is providing the following revised guidance for the full year ending December 31, 2008:
-- Increasing expected test results delivered to 38,000 to 40,000 test
results, from previous guidance of 34,000 to 37,000 test results.
-- Projecting total revenue in a range between $105 million and $110
million, compared to previous guidance of $100 million to $110 million,
with an expectation that full-year revenue may be at the higher end of
this guidance.
-- Continuing to expect net loss of $15 million to $20 million for 2008,
with the net loss narrowing in the second half of 2008 as compared to
the first half of 2008.
Recent Highlights and Accomplishments
Physician Usage and Adoption
-- More than 9,690 test results were delivered in the second quarter of
2008, compared to more than 5,750 test results delivered in the second
quarter of 2007.
-- More than 18,850 test results were delivered in the first half of 2008,
compared to more than 11,200 test results delivered in the first half
of 2007.
-- More than 65,000 Oncotype DX test results have been delivered to
patients.
Peer-Reviewed Publications and Medical Meeting Presentations
-- The Journal of Clinical Oncology published a study online showing that
the Oncotype DX Recurrence Score provides additional prognostic
information in patients with early-stage breast cancer beyond that
derived from Adjuvant! Online, an online tool that evaluates clinical
variables to help physicians and patients assess the risks and benefits
of getting additional therapy after surgery.
-- Two abstracts were accepted for presentation at the ASCO Breast Cancer
Symposium in September of 2008.
-- The Journal of Clinical Oncology published results of a study
demonstrating the utility of Oncotype DX in measuring quantitative gene
expression for ER and PR status, indicating that quantitative RT-PCR,
as performed in the Oncotype DX breast cancer assay, is a reliable
method for determining hormone receptor status in breast cancer.
-- Presented results from two initial studies with collaborators that
could lead to the development of new tests for predicting benefit from
certain targeted therapies in cancer, at the 2008 ASCO meeting in June.
Reimbursement Progress for Oncotype DX
-- In June, Palmetto GBA, the company that will replace National Heritage
Insurance Company (NHIC) as the Medicare administrative contractor,
posted local coverage decisions for its jurisdiction that included
Oncotype DX. This coverage decision follows the identical criteria
previously set forth by NHIC. We expect to begin processing claims with
Palmetto in September of 2008.
-- Gained coverage for over 6.9 million additional lives for access to
Oncotype DX.
o Blue Cross Blue Shield plans of Louisiana, Mississippi and
Northeastern Pennsylvania established policies covering approximately
2.3 million lives.
o Group Health Incorporated and HIP Health Plan of New York established
policies covering approximately 4.6 million lives.
Product Pipeline
Breast Cancer
-- Targeting inclusion of quantitative HER2 scores in all Oncotype DX
reports by the end of 2008.
-- Conducting a study using Oncotype DX in breast cancer patients treated
with aromatase inhibitors with the goal of reporting results this year.
Colon Cancer
-- Received first trial specimens for our clinical validation study, which
we expect to begin in the second half of 2008.
-- Received milestone payment from Bristol-Myers Squibb related to Genomic
Health's program to identify genes to predict response to cetuximab
(Erbitux®).
Other Cancers
-- Established collaborators and identified sources of clinical samples
to further our prostate and lung cancer programs.
-- Began gene identification work to develop a prognostic test for
patients with renal cell carcinoma, clear cell type, under the Pfizer
collaboration announced in January of 2008.
International
-- Initiated a study supporting Japanese investigators as they gain
clinical experience with Oncotype DX for early-stage breast cancer
patients.
-- Processing samples from patients in Canada, Ireland and Peru enrolled
in the National Cancer Institute-sponsored TAILORx study, which has
expanded internationally.
Conference Call Details
To access the live conference call today, August 5, at 4:30 p.m. Eastern Time via phone, please dial (877) 356-8064 from the United States and Canada or (706) 758-4314 internationally. The conference ID is 56195752. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through August 12 and may be accessed by dialing (800) 642-1687 from the United States and Canada or (706) 645-9291 internationally. The replay passcode is 56195752.
To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's Web site at http://investor.genomichealth.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.
surf1944
16 years ago
Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores
Monday June 2, 8:30 am ET
Study Published in the Journal of Clinical Oncology Proves Accurate Measurement of ER and PR Status Using Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)
REDWOOD CITY, Calif., June 2 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX - News) today announced that the Journal of Clinical Oncology (JCO) published results of a study confirming RT-PCR by Oncotype DX can deliver quantitative gene expression levels for assessing estrogen receptor (ER) and progesterone receptor (PR) status, which are critical factors in determining the use and benefit of hormonal therapy for the treatment of breast cancer. Based on these results, Genomic Health is now providing quantitative ER and PR scores to physicians and patients in addition to the Recurrence Score(TM) result provided in the Oncotype DX® report.
Unlike traditional methodologies that provide either a positive or negative result, or a semi-quantitative result, RT-PCR by Oncotype DX generates a specific score across a continuous range of expression which allows physicians to factor the quantitative level of ER and PR gene expression into their treatment planning.
"Every breast tumor expresses the estrogen receptor gene at a specific level and, similar to other diagnostic measures, the ability to more accurately pinpoint that level increases the confidence in a diagnosis and treatment plan," said Sandra Swain, M.D., Medical Director, Washington Cancer Institute, Washington Hospital Center. "Having quantitative ER and PR scores provides added certainty in confirming expression levels of these important genes in predicting how likely a patient is to benefit from hormonal therapy."
This study published in JCO was originally presented at the American Society of Clinical Oncology Breast Cancer Symposium in September 2007. It measured ER and PR gene expression in 776 breast cancer patients by both local laboratory and central immunohistochemistry (IHC), and quantitative RT-PCR, as performed by the Oncotype DX assay. Results showed a high degree of agreement between the two methods. In an accompanying editorial, Dr. Craig Allred comments, "RT-PCR is at least equivalent to IHC in its ability to identify receptor-positive cases (considering ER and PR combined), marginally superior in predicting outcome in ER-positive patients, and superior in technical precision."
"We believe the methodology of the future is the quantitative measure of the biology of each individual tumor," said Steven Shak, M.D., chief medical officer of Genomic Health. "Providing physicians with quantitative ER and PR scores enhances the value of Oncotype DX by providing more patient-specific information to help individualize treatment decisions for breast cancer patients. We are continuing to conduct additional studies, including studying the use of RT-PCR by Oncotype DX to quantify HER-2 gene expression, another cancer-related gene that plays an important role in the determination of optimal treatment for breast cancer patients."
About Oncotype DX®
Oncotype DX is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 3,600 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, 7,500 physicians have ordered more than 55,000 tests, and health plans covering over 80 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Ask ADVFN Intelligence (AI)
whytestocks
5 years ago
rocknroll350
6 years ago
crudeoil24
6 years ago
Hot Features
Premium
